AACAP’s 2020 Pediatric Psychopharmacology Update Institute, Translating Advances in Pediatric Psychopharmacology into Practice: Molecules, Mechanisms and Medications, highlights the shifting emphasis to neuroscience-based medication nomenclature and understanding the pharmacology of psychotropic medications that provide the basis for contemporary approaches to medication management across the range of clinical conditions commonly treated by child and adolescent psychiatrists. Nine top child and adolescent psychiatric research clinicians describe updated frameworks for categorizing sychiatric medications, understanding where and how these medications work in psychiatric treatments, how to make practical use of this understanding in clinical patient care, and how advances in neuromodulation and pharmacogenetics might potentially expand the clinical armamentarium. At the end of the Institute, participants will be familiar with new ways of classifying psychotropic medications as defined by the World Health Organization and other international groups, be thoroughly familiar with clinically-relevant mechanisms of action and pharmacological properties of medications commonly used in psychiatric treatments, and with reference to these mechanisms and pharmacological properties, understand best practice approaches to treating ADHD, mood disorders, anxiety and trauma, and psychosis. Mechanisms and evidence supporting clinical use of neuromodulation and pharmacogenetics will also be discussed.
Educational Learning Objectives
At the conclusion of this CME activity, the participant will be able to:
- Categorize medications commonly used in psychiatric practice using the newly adopted Neuroscience-based Nomenclature (NbN) in accordance with definitions established by the
World Health Organization.
- Describe presumed targets and mechanisms of drug activity that provide a basis for choice and use of medications in clinical treatment.
- Utilize enhanced understanding of drug mechanisms and properties in making clinical decisions for initiation, maintenance, and cessation of medication therapies in treating
disorders commonly treated by child and adolescent psychiatrists.